Overview
Please see the Duke Nephrology Division website for more detailed information.
Current Appointments & Affiliations
Professor of Medicine
·
2012 - Present
Medicine, Nephrology,
Medicine
Member of the Duke Cancer Institute
·
1983 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Podocyte specific knockout of the natriuretic peptide clearance receptor is podocyte protective in focal segmental glomerulosclerosis.
Journal Article PLoS One · 2025 Natriuretic peptides (NPs) bind to glomerular podocytes and attenuate glomerular injury. The beneficial effects of NPs are negatively regulated by the NP clearance receptor (NPRC), which is highly expressed in podocytes. To determine if inhibiting NPRC is ... Full text Link to item CitePharmacologic blockade of the natriuretic peptide clearance receptor promotes weight loss and enhances insulin sensitivity in type 2 diabetes.
Journal Article Transl Res · May 2023 While natriuretic peptides (NPs) are primarily known for their renal and cardiovascular actions, NPs stimulate lipolysis in adipocytes and induce a thermogenic program in white adipose tissue (WAT) that resembles brown fat. The biologic effects of NPs are ... Full text Link to item CiteBlockade of the natriuretic peptide clearance receptor attenuates proteinuria in a mouse model of focal segmental glomerulosclerosis.
Journal Article Physiol Rep · November 2021 Glomerular podocytes play a key role in proteinuric diseases. Accumulating evidence suggests that cGMP signaling has podocyte protective effects. The major source of cGMP generation in podocytes is natriuretic peptides. The natriuretic peptide clearance re ... Full text Link to item CiteRecent Grants
U2C/TL1 NC KUH TRIO Administrative Core
ResearchCo Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028REGULATORS OF CALCINEURIN PATHWAYS AS DIAGNOSTIC AND THERAPEUTIC TARGETS FOR NEPHROTIC SYNDROME
ResearchInvestigator · Awarded by National Institutes of Health · 2023 - 2026A Novel Therapeutic Approach to Treat Focal Segmental Glomerulosclerosis (FSGS) R21
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2025View All Grants
Education, Training & Certifications
Ohio State University ·
1983
M.D.